Retrieve available abstracts of 289 articles: HTML format
Single Articles
June 2025
CHEN H A disproportionality analysis of nervous system adverse events associated with
disease-modifying therapies in multiple sclerosis: insights from the FDA adverse
event reporting system (FAERS).
J Neurol. 2025;272:445. PubMedAbstract available
MALUCCHI S, Bava CI, Valentino P, Martire S, et al Correction: In multiple sclerosis patients a single serum neurofilament light
chain (sNFL) dosage is strongly associated with 12 months outcome: data from a
real-life clinical setting.
J Neurol. 2025;272:444. PubMed
GERAN R, Steiner OL, Krasivskaya E, Hannemann U, et al Inverse relation between serum neurofilament light chain and cognitive function
in chronic inflammatory demyelinating polyneuropathy.
J Neurol. 2025;272:439. PubMedAbstract available
May 2025
MACCORA S, Vinciguerra C, Messina C, Bevilacqua L, et al Double seronegative myasthenia gravis and mimics: a retrospective cross-sectional
study by two tertiary centers in the Southern Italy.
J Neurol. 2025;272:433. PubMedAbstract available
NEYAL N, Krey KJ, Morrison HA, Nathoo N, et al From checkboxes to emojis: a novel approach to patient-reported outcomes in
multiple sclerosis.
J Neurol. 2025;272:434. PubMedAbstract available
GASPERINI C, Centonze D, Conte A, Gallo P, et al Personalized therapy in multiple sclerosis: an Italian Delphi consensus.
J Neurol. 2025;272:428. PubMedAbstract available
CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al Correction: Pharmacogenomics of clinical response to Natalizumab in multiple
sclerosis: a genome-wide multi-centric association study.
J Neurol. 2025;272:423. PubMed
ARZALLUZ-LUQUE J, Dumez P, Picard G, Benaiteau M, et al Clinical course and long-term outcomes in autoimmune glial fibrillary acidic
protein (GFAP) astrocytopathy.
J Neurol. 2025;272:421. PubMedAbstract available
GIOFRE F, Lugaresi A, Baccari F, Lui E, et al The topography of infratentorial lesions in depression and anxiety in multiple
sclerosis.
J Neurol. 2025;272:420. PubMedAbstract available
PIGNOLO A, Vinciguerra C, Monastero R, Rini N, et al Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65
autoantibody: a systematic review.
J Neurol. 2025;272:417. PubMedAbstract available
DAVIES L, Shehadeh R, Watkins WJ, Jolles S, et al Real-world observational study of infections in people treated with ocrelizumab
for multiple sclerosis.
J Neurol. 2025;272:415. PubMedAbstract available
CAO S, Zhou X, Du J, Zhang J, et al Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.
J Neurol. 2025;272:406. PubMedAbstract available
ZHANG Y, Li G, Su H, Liang Y, et al Effects of exercise on balance function in people with multiple sclerosis: a
systematic review and meta-analysis of randomized controlled trials.
J Neurol. 2025;272:405. PubMedAbstract available
GERVASONI E, Torchio A, Bertoni R, Chieffo R, et al Beyond EDSS: multidomain impairments are detectable and associated with walking
disorders in low-disabled people with multiple sclerosis.
J Neurol. 2025;272:404. PubMedAbstract available
WANG Z, Tan H, Huang W, Fan Y, et al Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in
neuromyelitis optica spectrum disorder.
J Neurol. 2025;272:403. PubMedAbstract available
FREEDMAN MS, Abdelhak A, Bhutani MK, Freeman J, et al The role of serum neurofilament light (sNfL) as a biomarker in multiple
sclerosis: insights from a systematic review.
J Neurol. 2025;272:400. PubMedAbstract available
KIM YS, Shin IJ, Park DG, Yoon JH, et al Hashimoto's encephalopathy with diffuse leukoencephalopathy: serial MRI and gait
analysis.
J Neurol. 2025;272:399. PubMed
ROSSINI E, Di Stefano V, Iorio R, Habetswallner F, et al Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life
experience.
J Neurol. 2025;272:396. PubMedAbstract available
TARANU D, Balz LT, Holbrook J, Tumani V, et al Cognitive impairment, mood, and fatigue in various multiple sclerosis subtypes: a
one-year follow-up study.
J Neurol. 2025;272:398. PubMedAbstract available
ROCCA MA, Ratzinger S, Preziosa P, Meani A, et al Clinical integration of brain and cord MRI features improves differential
diagnosis of multiple sclerosis.
J Neurol. 2025;272:388. PubMedAbstract available
HU S, Liao Z, Wang R, Zhang M, et al Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum
disorders: a multi-center retrospective cohort study.
J Neurol. 2025;272:387. PubMedAbstract available
FILIPPI M, Preziosa P, Rocca MA Randomized controlled trials for multiple sclerosis: integrating pathology-driven
outcomes to capture therapeutic efficacy.
J Neurol. 2025;272:385. PubMed
ROY S, Huang Y, Hu C, Fitzgerald KC, et al Core diagnostic features of stiff person syndrome: insights from a case-control
study.
J Neurol. 2025;272:377. PubMedAbstract available
FREEDMAN DE, Oh J, Einstein G, Feinstein A, et al Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.
J Neurol. 2025;272:375. PubMedAbstract available
KOLB H, Shachaf Y, Fainberg K, Golan M, et al Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label
study with long-term follow-up.
J Neurol. 2025;272:374. PubMedAbstract available
HERMAN D, Tanniou J, Leray E, Pierret C, et al Analyzing recurrent events in multiple sclerosis: a review of statistical models
with application to the MSOAC database.
J Neurol. 2025;272:371. PubMedAbstract available
KUUTTI K, Laakso SM, Viitala M, Atula S, et al Mortality and causes of death for people with multiple sclerosis: a Finnish
nationwide register study.
J Neurol. 2025;272:370. PubMedAbstract available
April 2025
CACCIAGUERRA L, Madhavan A, Sechi E, Krecke KN, et al Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple
sclerosis.
J Neurol. 2025;272:367. PubMed
PANE C, Di Stefano V, Cuomo N, Sarnataro A, et al Correction: A real-life experience with eculizumab and efgartigimod in
generalized myasthenia gravis patients.
J Neurol. 2025;272:366. PubMed
SEERY N, Wesselingh R, Beech P, Broadley J, et al Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune
encephalitis consortium study.
J Neurol. 2025;272:361. PubMedAbstract available
MAHMOUDI N, Renne J, Konen FF, Jendretzky KF, et al Added value of optic nerve lesions for multiple sclerosis diagnostic criteria.
J Neurol. 2025;272:358. PubMedAbstract available
CAMPETELLA L, Smolik K, Farina A, Joubert B, et al Neurodegeneration and the immune system: lessons from autoimmune encephalitis.
J Neurol. 2025;272:359. PubMedAbstract available
SIRIRATNAM P, Huda S, Van der Walt A, Sanfilippo P, et al Progression independent of relapse activity and relapse-associated worsening in
seronegative NMOSD: an international cohort study.
J Neurol. 2025;272:339. PubMedAbstract available
LEAVITT V, Mostert J, Comtois J, Moral E, et al Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND
cognition substudy.
J Neurol. 2025;272:338. PubMedAbstract available
BALSHI A, Dempsey J, Kumbar S, Leuenberger G, et al Correction: Marriage is associated with decreased lesion volumes and less brain
atrophy in people with multiple sclerosis.
J Neurol. 2025;272:337. PubMed
OJHA A, Tommasin S, Piervincenzi C, Baione V, et al Clinical and MRI features contributing to the clinico-radiological dissociation
in a large cohort of people with multiple sclerosis.
J Neurol. 2025;272:327. PubMedAbstract available
HONG J, Gaubert M, Lefort M, Ferre JC, et al Limited added value of systematic spinal cord MRI vs brain MRI alone to classify
patients with MS as active or inactive during follow-up.
J Neurol. 2025;272:316. PubMedAbstract available
MOIOLA L, Mandelli A, Tarkowski M, Finardi A, et al Recall vaccination increases detectable B-cell reactivity in persons with
multiple sclerosis treated with ocrelizumab.
J Neurol. 2025;272:314. PubMedAbstract available
LADOPOULOS T, Abbas Z, Krieger B, Bellenberg B, et al Neurological disability and brain grey matter atrophy in primary progressive
multiple sclerosis are determined by microstructural lesional changes, but not by
lesion load.
J Neurol. 2025;272:302. PubMedAbstract available
March 2025
KONITSIOTI AM, Laurent S, Ellenberger D, Stahmann A, et al MS treatment trends before, during, and after the COVID-19 pandemic: insights
from the German MS Register.
J Neurol. 2025;272:294. PubMedAbstract available
KHERBEK H, Paramasivan NK, Dasari S, Karsten C, et al Exploring autoantigens in autoimmune limbic encephalitis using phage
immunoprecipitation sequencing.
J Neurol. 2025;272:292. PubMedAbstract available
RITTEL JC, Hudasch D, Doppler K, Bergh FT, et al Intravenous immunoglobulin as first-line acute treatment in adults with
autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2.
J Neurol. 2025;272:287. PubMedAbstract available
LADEIRA F, Nobrega C, Cerqueira J Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses
in immunocompromised patients with multiple sclerosis: the COVACiMS study.
J Neurol. 2025;272:288. PubMedAbstract available
FUJII S, Yaguchi H, Kudo A, Eguchi K, et al Autoimmune cerebellar ataxia with Kelch-like protein 11 antibodies in a large
cohort study.
J Neurol. 2025;272:282. PubMed
FARINA A, Villagran-Garcia M, Abichou-Klich A, Benaiteau M, et al Application of the anti-IgLON5 disease composite score to assess severity,
clinical course, and mortality in a French cohort.
J Neurol. 2025;272:273. PubMedAbstract available
BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia
gravis: the randomized open-label extension MG0004 study.
J Neurol. 2025;272:275. PubMedAbstract available
DING Y, Wu D, Chu H, Tang Y, et al Clinical characterization of diseases associated with anti-N-methyl-D-aspartate
receptor encephalitis combined with anti-myelin oligodendrocyte glycoprotein
antibodies in adults.
J Neurol. 2025;272:262. PubMedAbstract available
SORENSEN NV, Nilsson AC, Dos AH, Stenor CM, et al Anti-GFAP associated opsoclonus-myoclonus-ataxia syndrome in a patient with
multiple autoimmune comorbidities-a case report.
J Neurol. 2025;272:263. PubMed
KOMATSU T, Motegi H, Mimori M, Okumura M, et al Predictors of achieving minimal manifestations or better status in ocular
myasthenia gravis with immunotherapy.
J Neurol. 2025;272:243. PubMedAbstract available
BOSTAN M, Li C, Cheong JW, Wong DWK, et al Longitudinal analysis of retinal and choriocapillaris in patients with multiple
sclerosis: a 3-year study.
J Neurol. 2025;272:237. PubMedAbstract available
February 2025
AZZIMONTI M, Preziosa P, Pagani E, Meani A, et al Cervical spinal cord gray matter damage predicts disability worsening in multiple
sclerosis: a longitudinal study.
J Neurol. 2025;272:228. PubMedAbstract available
PARAMASIVAN NK, Sarker P, Zekeridou A, Staff NP, et al Upper motor neuron-predominant motor neuron disease: a novel
immunotherapy-responsive association of GAD65 autoimmunity.
J Neurol. 2025;272:230. PubMedAbstract available
BINKS SNM, Morse IM, Ashraghi M, Vincent A, et al Myasthenia gravis in 2025: five new things and four hopes for the future.
J Neurol. 2025;272:226. PubMedAbstract available
SCHONHERR C, Ziegler J, Zentek T, Rashid A, et al Smartphone-based gait analysis in the assessment of fatigue and fatigability in
people with multiple sclerosis: a supervised cohort study.
J Neurol. 2025;272:217. PubMedAbstract available
BALSHI A, Dempsey J, Manning N, Leuenberger G, et al A disproportionality analysis of surgical site infections across multiple
sclerosis disease modifying therapies.
J Neurol. 2025;272:223. PubMedAbstract available
NAYAK S, Wagshul ME, Foley FW, Motl RW, et al Associations between connectivity in functional brain networks and gait speed in
older adults with and without multiple sclerosis.
J Neurol. 2025;272:216. PubMedAbstract available
DI SABATINO E, Ferraro D, Gaetani L, Emiliano E, et al CSF biomarkers of B-cell activation in multiple sclerosis: a clinical
perspective.
J Neurol. 2025;272:211. PubMedAbstract available
MARASTONI D, Sicchieri M, Pizzini FB, Scartezzini A, et al Multiple sclerosis diagnosis and its differential diagnosis in patients
presenting with type four 'mirror pattern' CSF oligoclonal bands.
J Neurol. 2025;272:207. PubMedAbstract available
NISHIMORI Y, Tanboon J, Oyama M, Motegi H, et al Anti-mitochondrial M2 antibody-positive myositis may be an independent subtype of
autoimmune myositis.
J Neurol. 2025;272:206. PubMedAbstract available
CHEN X, Wang R, Li R, Hu S, et al A real-world study on the utility of regular rituximab treatment for
neuromyelitis optica spectrum disorder.
J Neurol. 2025;272:194. PubMedAbstract available
FILIPPI M, Amato MP, Avolio C, Gallo P, et al Towards a biological view of multiple sclerosis from early subtle to clinical
progression: an expert opinion.
J Neurol. 2025;272:179. PubMedAbstract available
HANSEL M, Reichmann H, Haehner A, Schmitz-Peiffer H, et al Hippocampal dysfunction after autoimmune encephalitis depending on the antibody
type.
J Neurol. 2025;272:175. PubMedAbstract available
January 2025
GIANNOPAPAS V, Smyrni V, Kitsos DK, Stefanou MI, et al Cancer in multiple sclerosis patients following prolonged exposure to
disease-modifying therapies (DMTs): a systematic review and meta-analysis.
J Neurol. 2025;272:162. PubMedAbstract available
DE ARMAS FERNANDEZ JR, Garcia CEP, Herrera BA, Garcia FD, et al Incidence of Guillain-Barre syndrome in Cuba before and during the Oropouche
virus emergency, 2018-2024.
J Neurol. 2025;272:164. PubMed
BOAVENTURA M, Fragoso DC, Avolio I, Pereira SA, et al Brain tissue integrity in neuromyelitis optica spectrum disorder through
T1-w/T2-w ratio, MTR and DTI.
J Neurol. 2025;272:157. PubMedAbstract available
INOJOSA H, Schriefer D, Ness NH, Dillenseger A, et al Cost-consequence analysis of early vs. delayed natalizumab use in highly active
relapsing-remitting multiple sclerosis: a simulation study.
J Neurol. 2025;272:153. PubMedAbstract available
PIHL-JENSEN G, Frederiksen JL The value of magnetic resonance imaging of the optic nerve for the diagnosis of
multiple sclerosis in patients with optic neuritis.
J Neurol. 2025;272:131. PubMedAbstract available
LAGEMAN SB, Jolly A, Sahi N, Prados F, et al Explaining cognitive function in multiple sclerosis through networks of grey and
white matter features: a joint independent component analysis.
J Neurol. 2025;272:142. PubMedAbstract available
MIRMOSAYYEB O, Weinstock-Guttman B, Zivadinov R, Jakimovski D, et al Anatomy-driven segmentation of parafoveal optical coherence tomography (OCT)
measures may improve associations with clinical outcomes in multiple sclerosis.
J Neurol. 2025;272:141. PubMedAbstract available
BALSHI A, Dempsey J, Kumbar S, Leunberger G, et al Marriage is associated with decreased lesion volumes and less brain atrophy in
people with multiple sclerosis.
J Neurol. 2025;272:151. PubMedAbstract available
MAR S, Valeriani M, Steinborn B, Schreiner T, et al Ocrelizumab dose selection for treatment of pediatric relapsing-remitting
multiple sclerosis: results of the OPERETTA I study.
J Neurol. 2025;272:137. PubMedAbstract available
MAIWORM M, Koerbel K, Anschutz V, Jakob J, et al BDNF levels in serum and CSF are associated with clinicoradiological
characteristics of aggressive disease in MS patients.
J Neurol. 2025;272:147. PubMedAbstract available
PREZIOSA P, Pagani E, Meani A, Margoni M, et al Soma and neurite density abnormalities of paramagnetic rim lesions and core-sign
lesions in multiple sclerosis.
J Neurol. 2025;272:145. PubMedAbstract available
PLESS S, Woelfle T, Lorscheider J, Wiencierz A, et al CoGames: Development of an adaptive smartphone-based and gamified monitoring tool
for cognitive function in Multiple Sclerosis.
J Neurol. 2025;272:119. PubMedAbstract available
ZANGHI A, Greco A, Giancipoli E, Tumani H, et al Unraveling the inflammation-degeneration tangle in early MS: preliminary insights
from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.
J Neurol. 2025;272:109. PubMedAbstract available
FOCKE JK, Brokbals M, Becker J, Veltkamp R, et al Cerebral vasculitis related to neurosarcoidosis: a case series and systematic
literature review.
J Neurol. 2025;272:135. PubMedAbstract available
LIU M, Ren H, Yao D, Yao M, et al Autoimmune cerebellar ataxia associated with anti-SEZ6L2 antibody: report of
three cases.
J Neurol. 2025;272:127. PubMed
ROBERTSON NP Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false
dawn.
J Neurol. 2025;272:106. PubMedAbstract available
FAROOQI AM, Sawalha A, Omidi SJ, Dubey D, et al Seizures and status epilepticus in anti-NMDA receptor encephalitis.
J Neurol. 2025;272:95. PubMedAbstract available
WALBAUM M, Madhukar A, Dobson R, Cyhlarova E, et al Cost effectiveness of different treatment strategies with natalizumab for
pregnant women with multiple sclerosis.
J Neurol. 2025;272:93. PubMedAbstract available
FILIPPI M, Gallo P, Gasperini C, Marfia GA, et al Implementing proximity care for people with multiple sclerosis in Italy: the
bottom-up approach of the StayHome project.
J Neurol. 2025;272:96. PubMedAbstract available
SCHUMACHER A, Hieke A, Spenner M, Schmitz F, et al Early therapy initiation is crucial in chronic inflammatory demyelinating
polyneuropathy: prospective multimodal data from the German INHIBIT registry.
J Neurol. 2025;272:100. PubMedAbstract available
December 2024
NICOLESCU M, Haussler V, Paul F, Oertel FC, et al Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations
with ageing and vision.
J Neurol. 2024;272:86. PubMedAbstract available
BARBA L, Gaetani L, Sperandei S, Di Sabatino E, et al CSF synaptic biomarkers and cognitive impairment in multiple sclerosis.
J Neurol. 2024;272:85. PubMedAbstract available
MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al Magnetic resonance imaging-based biomarkers of multiple sclerosis and
neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
J Neurol. 2024;272:77. PubMedAbstract available
INAN B, Ozturk B, Ata N, Ulgu MM, et al A nationwide epidemiological study of myasthenia gravis in Turkey.
J Neurol. 2024;272:5. PubMedAbstract available
VECCHIO D, Puricelli C, Virgilio E, Passarelli F, et al Kappa index for multiple sclerosis diagnosis: an accurate biomarker of
intrathecal synthesis.
J Neurol. 2024;272:30. PubMedAbstract available
PONZIO M, Santoni L, Molina M, Tavazzi E, et al Economic burden of multiple sclerosis in an Italian cohort of patients on
disease-modifying therapy: analysis of disease cost and its components.
J Neurol. 2024;272:50. PubMedAbstract available
DE BLASIIS P, Massimiani A, Inglese C, Bianchini E, et al Spasticity patterns assessment and recognition for therapeutic approaches
(SPARTA) in multiple sclerosis: a multicenter epidemiological study.
J Neurol. 2024;272:34. PubMedAbstract available
KLIMAS R, Sturm D, Altenborg A, Stylianou N, et al Assessing axonal pathology and disease progression in chronic inflammatory
demyelinating polyneuropathy using corneal confocal microscopy.
J Neurol. 2024;272:51. PubMedAbstract available
BUGGE C, Engebretsen I, Kristiansen IS, Saether EM, et al Medical costs of treating myasthenia gravis in patients who need intravenous
immunoglobulin (IVIg) - a register-based study.
J Neurol. 2024;272:15. PubMedAbstract available
FASANO C, Bettiol A, Vastola M, Lotti A, et al Effectiveness and safety of intravenous immunoglobulin for peripheral neuropathy
in EGPA patients: a retrospective study.
J Neurol. 2024;272:13. PubMedAbstract available
GASPERINI C, Battaglia MA, Balzani F, Chiarini E, et al Unveiling preferences in multiple sclerosis care: insights from an Italian
discrete-choice experiment with patients and healthcare professionals.
J Neurol. 2024;272:27. PubMedAbstract available
COMABELLA M, Hegen H, Villar LM, Rejdak K, et al Increased EBNA1-specific antibody response in primary-progressive multiple
sclerosis.
J Neurol. 2024;272:26. PubMedAbstract available
MARLET IR, Andersen RK, Axelsen KH, Andersen LK, et al Factors affecting the diagnostic delay of myasthenia gravis.
J Neurol. 2024;272:29. PubMedAbstract available
FILIPPI M, Margoni M, Zaccone T, Guerrieri S, et al Disability worsening outcome in multiple sclerosis based on EDSS: does half a
point matter?
J Neurol. 2024;272:9. PubMed
November 2024
PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al Rapid differentiation of MOGAD and MS after a single optic neuritis.
J Neurol. 2024;271:7222-7231. PubMedAbstract available
October 2024
FACCIORUSSO S, Malfitano C, Giordano M, Del Furia MJ, et al Effectiveness of robotic rehabilitation for gait and balance in people with
multiple sclerosis: a systematic review.
J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12715. PubMedAbstract available
TARD C, Laforet P, de Pouvourville G, Crochard A, et al Treatment of myasthenia gravis in france: A retrospective claims database study
(STAMINA).
J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12714. PubMedAbstract available
MOSER T, Gruber J, Mylonaki E, Bohm V, et al Autoimmune and infectious encephalitis: development of a discriminative tool for
early diagnosis and initiation of therapy.
J Neurol. 2024 Oct 5. doi: 10.1007/s00415-024-12712. PubMedAbstract available
BALCK A, Lange LM, Neumann A, Royl G, et al Highly beneficial outcome in severe acute necrotizing encephalopathy with
tocilizumab treatment.
J Neurol. 2024;271:7042-7045. PubMed
SELMAJ K, Hartung HP, Mycko MP, Selmaj I, et al MS treatment de-escalation: review and commentary.
J Neurol. 2024;271:6426-6438. PubMedAbstract available
September 2024
MALUCCHI S, Bava CI, Valentino P, Martire S, et al In multiple sclerosis patients a single serum neurofilament light chain (sNFL)
dosage is strongly associated with 12 months outcome: data from a real-life
clinical setting.
J Neurol. 2024 Sep 23. doi: 10.1007/s00415-024-12701. PubMedAbstract available
PEKMEZOVIC T, Jovicevic V, Andabaka M, Momcilovic N, et al Aquaporin4-IgG seropositivity significantly increases the risk of comorbid
autoimmune diseases in NMOSD patients: population-based registry data.
J Neurol. 2024 Sep 22. doi: 10.1007/s00415-024-12698. PubMedAbstract available
MARGONI M, Valsasina P, Moiola L, Mistri D, et al Monoaminergic network abnormalities are associated with fatigue in pediatric
multiple sclerosis.
J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12689. PubMedAbstract available
MENG H, He L, Chunyu H, Zhou Q, et al (18)F-DPA714 PET/MRI as a potential imaging tool for detecting possible
antibody-negative autoimmune encephalitis: a prospective study.
J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12690. PubMedAbstract available
MANGIORIS G, Orozco E, Dubey D, Flanagan EP, et al Long-term outcomes in antibody-negative autoimmune encephalitis: a retrospective
study.
J Neurol. 2024 Sep 15. doi: 10.1007/s00415-024-12680. PubMedAbstract available
KONITSIOTI AM, Pruss H, Laurent S, Fink GR, et al Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central
nervous system: a systematic literature review.
J Neurol. 2024 Sep 14. doi: 10.1007/s00415-024-12642. PubMedAbstract available
YOUSEF H, Malagurski Tortei B, Castiglione F Predicting multiple sclerosis disease progression and outcomes with machine
learning and MRI-based biomarkers: a review.
J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12651. PubMedAbstract available
CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a
genome-wide multi-centric association study.
J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12608. PubMedAbstract available
HAFSTEINSDOTTIR B, Farman H, Lagerstrom N, Zetterberg H, et al Neurofilament light chain as a diagnostic and prognostic biomarker in
Guillain-Barre syndrome.
J Neurol. 2024 Sep 9. doi: 10.1007/s00415-024-12679. PubMedAbstract available
CALLEN AM, Zurawski J, Chu R, Tie Y, et al The role of 7 T MRI to assess atrophy of the subcortical deep gray matter in
relapsing-remitting multiple sclerosis.
J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12656. PubMedAbstract available
DELUCA J Correction to: Fatigue in multiple sclerosis: can we measure it and can we treat
it?
J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12630. PubMed
PORTACCIO E, Betti M, De Meo E, Addazio I, et al Correction to: Progression independent of relapse activity in relapsing multiple
sclerosis: impact and relationship with secondary progression.
J Neurol. 2024 Sep 4. doi: 10.1007/s00415-024-12627. PubMed
GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al Correction to: Unprescribed cannabinoids and multiple sclerosis: a multicenter,
cross-sectional, epidemiological study in Lombardy, Italy.
J Neurol. 2024 Sep 3. doi: 10.1007/s00415-024-12560. PubMed
SHI Z, Kong L, Wang R, Wang X, et al Cytomegalovirus and Epstein-Barr virus infections in patients with neuromyelitis
optica spectrum disorder.
J Neurol. 2024;271:6089-6095. PubMedAbstract available
QUINT P, Schroeter CB, Kohle F, Ozturk M, et al Preventing long-term disability in CIDP: the role of timely diagnosis and
treatment monitoring in a multicenter CIDP cohort.
J Neurol. 2024;271:5930-5943. PubMedAbstract available
HECHLER A, Kuchling J, Muller-Jensen L, Klag J, et al Hippocampal hub failure is linked to long-term memory impairment in
anti-NMDA-receptor encephalitis: insights from structural connectome graph
theoretical network analysis.
J Neurol. 2024;271:5886-5898. PubMedAbstract available
ABBOUD H, Sun R, Modak N, Elkasaby M, et al Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a
prospective observational study.
J Neurol. 2024;271:5875-5885. PubMedAbstract available
August 2024
WURDACK K, Pruss H, Finke C Evolution from viral encephalitis to autoimmune encephalitis to multiple
sclerosis: a case report.
J Neurol. 2024 Aug 31. doi: 10.1007/s00415-024-12659. PubMedAbstract available
CHISARI CG, Amato MP, Di Sapio A, Foschi M, et al Active and non-active secondary progressive multiple sclerosis patients exhibit
similar disability progression: results of an Italian MS registry study (ASPERA).
J Neurol. 2024 Aug 27. doi: 10.1007/s00415-024-12621. PubMedAbstract available
BAYAT M, Harbo T, Anzabi M, Bayat A, et al POLG-related mitochondrial disease mimicking autoimmune encephalitis.
J Neurol. 2024 Aug 24. doi: 10.1007/s00415-024-12641. PubMed
CAROTENUTO A, Di Monaco C, Papetti L, Borriello G, et al Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study
comparing natalizumab with fingolimod.
J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12610. PubMedAbstract available
SIMONE M, Lucisano G, Guerra T, Paolicelli D, et al Disability trajectories by progression independent of relapse activity status
differ in pediatric, adult and late-onset multiple sclerosis.
J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12638. PubMedAbstract available
MISCIOSCIA A, Mainero C, Treaba CA, Silvestri E, et al The contribution of paramagnetic rim and cortical lesions to physical and
cognitive disability at multiple sclerosis clinical onset: evaluating the power
of MRI and OCT biomarkers.
J Neurol. 2024 Aug 19. doi: 10.1007/s00415-024-12622. PubMedAbstract available
DUMEZ P, Villagran-Garcia M, Bani-Sadr A, Benaiteau M, et al Specific clinical and radiological characteristics of anti-NMDA receptor
autoimmune encephalitis following herpes encephalitis.
J Neurol. 2024 Aug 16. doi: 10.1007/s00415-024-12615. PubMedAbstract available
KOKUBUN N, Tsuchiya T, Hamaguchi M, Ueda Y, et al IgG subclass shifts occurring at acute exacerbations in autoimmune nodopathies.
J Neurol. 2024 Aug 2. doi: 10.1007/s00415-024-12597. PubMedAbstract available
ARNETT S, Chew SH, Leitner U, Hor JY, et al Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and
meta-analysis.
J Neurol. 2024;271:4794-4812. PubMedAbstract available
ARNETT SV, Prain K, Ramanathan S, Bhuta S, et al Long-term outcomes of ADEM-like and tumefactive presentations of CNS
demyelination: a case-comparison analysis.
J Neurol. 2024;271:5275-5289. PubMedAbstract available
KLIMAS R, Kordes A, Huckemann S, Gasz Z, et al The multiple roles of nerve biopsy in the diagnosis and prognosis of suspected
immune neuropathies.
J Neurol. 2024;271:5109-5121. PubMedAbstract available
RECHTMAN A, Freidman-Korn T, Zveik O, Shweiki L, et al Assessing the applicability of the 2023 international MOGAD panel criteria in
real-world clinical settings.
J Neurol. 2024;271:5102-5108. PubMedAbstract available
ZHANG L, Zhang Y, Li R, Zhu J, et al Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic
inflammatory demyelinating polyradiculoneuropathy.
J Neurol. 2024;271:4991-5002. PubMedAbstract available
COLY M, Adams D, Attarian S, Bouhour F, et al Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b
antibody syndrome.
J Neurol. 2024;271:4982-4990. PubMedAbstract available
ZIVADINOV R, Jakimovski D, Burnham A, Kuhle J, et al Neuroimaging assessment of facility-bound severely-affected MS reveals the
critical role of cortical gray matter pathology: results from the CASA-MS
case-controlled study.
J Neurol. 2024;271:4949-4962. PubMedAbstract available
July 2024
PANE C, Di Stefano V, Cuomo N, Sarnataro A, et al A real-life experience with eculizumab and efgartigimod in generalized myasthenia
gravis patients.
J Neurol. 2024 Jul 30. doi: 10.1007/s00415-024-12588. PubMedAbstract available
PAPATHANASIOU A, Tench CR, Ambrose PA, Sedehizadeh S, et al Pre-thymectomy disease severity predicts outcome in acetylcholine receptor
antibody-positive generalised myasthenia gravis.
J Neurol. 2024 Jul 30. doi: 10.1007/s00415-024-12592. PubMedAbstract available
FILIPPI M, Pagani E, Turrini R, Bartezaghi M, et al Effects of fingolimod on focal and diffuse damage in patients with
relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
J Neurol. 2024 Jul 29. doi: 10.1007/s00415-024-12590. PubMedAbstract available
MANZANO GS, Levy M, Salky R, Mateen FJ, et al Assessment of international MOGAD diagnostic criteria in patients with
overlapping MOG-associated disease and multiple sclerosis phenotypes.
J Neurol. 2024 Jul 27. doi: 10.1007/s00415-024-12585. PubMedAbstract available
MITOMA H, Manto M Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel
concepts and fundamental questions on autoimmune mechanisms.
J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12596. PubMedAbstract available
PASSALI M, Galea I, Knudsen MH, Lau LC, et al Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its
predictive ability of multiple sclerosis.
J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12587. PubMedAbstract available
HABIB AA, Klink AJ, Muppidi S, Parthan A, et al United States clinical practice experience with eculizumab in myasthenia gravis:
symptoms, function, and immunosuppressant therapy use.
J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12569. PubMedAbstract available
KARL AS, Klimas R, Katsimpoura M, Sgodzai M, et al Quality of life and tolerability of B-cell directed therapy of multiple sclerosis
with ofatumumab in a patient-centered real-world observational study.
J Neurol. 2024 Jul 22. doi: 10.1007/s00415-024-12581. PubMedAbstract available
MOLENAAR PCG, Noteboom S, van Nederpelt DR, Krijnen EA, et al Digital outcome measures are associated with brain atrophy in patients with
multiple sclerosis.
J Neurol. 2024 Jul 15. doi: 10.1007/s00415-024-12516. PubMedAbstract available
RAVANO V, Andelova M, Piredda GF, Sommer S, et al Microstructural characterization of multiple sclerosis lesion phenotypes using
multiparametric longitudinal analysis.
J Neurol. 2024 Jul 13. doi: 10.1007/s00415-024-12568. PubMedAbstract available
VITI V, Zanetta C, Capra R, Municchi A, et al Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging
safety issue.
J Neurol. 2024 Jul 11. doi: 10.1007/s00415-024-12553. PubMed
ZHU F, Wang WF, Ma CH, Liang H, et al Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after
treatment with efgartigimod.
J Neurol. 2024 Jul 9. doi: 10.1007/s00415-024-12556. PubMedAbstract available
DELUCA J Fatigue in multiple sclerosis: can we measure it and can we treat it?
J Neurol. 2024 Jul 5. doi: 10.1007/s00415-024-12524. PubMedAbstract available
ROT U, Jerala M, Horvat Ledinek A, Brecl Jakob G, et al Progressive multifocal leukoencephalopathy in association with siponimod
treatment for secondary progressive multiple sclerosis: a case report.
J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12542. PubMed
PREZIOSA P, Amato MP, Battistini L, Capobianco M, et al Moving towards a new era for the treatment of neuromyelitis optica spectrum
disorders.
J Neurol. 2024;271:3879-3896. PubMedAbstract available
KAPPOS L, Edan G, Freedman MS, Hartung HP, et al Long-term clinical outcomes in patients with CIS treated with interferon beta-1b:
results from the 15-year follow up of the BENEFIT trial.
J Neurol. 2024;271:4599-4609. PubMedAbstract available
ZANGHI A, Borriello G, Bonavita S, Fantozzi R, et al Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score
matched study.
J Neurol. 2024;271:4495-4502. PubMedAbstract available
WANG R, Sun D, Wang X, Shi Z, et al Correlation between severe attacks and serum aquaporin-4 antibody titer in
neuromyelitis optica spectrum disorder.
J Neurol. 2024;271:4503-4512. PubMedAbstract available
HARTUNG HP, Berger T, Bermel RA, Brochet B, et al ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized
controlled trial.
J Neurol. 2024;271:4348-4360. PubMedAbstract available
PESTCHANKER C, Bertado Cortez B, Lana Peixoto MA, Gortari JI, et al Occurrence of area postrema syndrome during follow-up: phenotype and influence
over NMOSD activity in LATAM in real-world settings.
J Neurol. 2024;271:4292-4299. PubMedAbstract available
MAKHANI N, Lebrun-Frenay C, Siva A, Shabanova V, et al The diagnostic workup of children with the radiologically isolated syndrome
differs by age and by sex.
J Neurol. 2024;271:4019-4027. PubMedAbstract available
June 2024
LAL AP, Foong YC, Sanfilippo PG, Spelman T, et al A multi-centre longitudinal study analysing multiple sclerosis disease-modifying
therapy prescribing patterns during the COVID-19 pandemic.
J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518. PubMedAbstract available
GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al Memory function in autoimmune encephalitis: a cross-sectional prospective study
utilising multiple memory paradigms.
J Neurol. 2024 Jun 25. doi: 10.1007/s00415-024-12520. PubMedAbstract available
NOTEBOOM S, Seiler M, Chien C, Rane RP, et al Evaluation of machine learning-based classification of clinical impairment and
prediction of clinical worsening in multiple sclerosis.
J Neurol. 2024 Jun 23. doi: 10.1007/s00415-024-12507. PubMedAbstract available
SIMANI L, Molaeipour L, Kian S, Leavitt VM, et al Correlation between cognitive changes and neuroradiological changes over time in
multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2024 Jun 18. doi: 10.1007/s00415-024-12517. PubMedAbstract available
FUNKE M, Eveslage M, Zschuntzsch J, Hagenacker T, et al Fatigue and associated factors in myasthenia gravis: a nationwide registry study.
J Neurol. 2024 Jun 13. doi: 10.1007/s00415-024-12490. PubMedAbstract available
YU H, Wang X, Pan Y, Li H, et al Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer
patient: a case report and literature review.
J Neurol. 2024 Jun 12. doi: 10.1007/s00415-024-12494. PubMedAbstract available
KONG X, Guo K, Liu X, Gong X, et al Differentiation between viral and autoimmune limbic encephalitis: a prospective
cohort study with development and validation of a diagnostic model.
J Neurol. 2024 Jun 11. doi: 10.1007/s00415-024-12468. PubMedAbstract available
GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional,
epidemiological study in Lombardy, Italy.
J Neurol. 2024 Jun 7. doi: 10.1007/s00415-024-12472. PubMedAbstract available
MUCK A, Pfeuffer S, Mir L, Genau S, et al Myasthenic crises are associated with negative long-term outcomes in myasthenia
gravis.
J Neurol. 2024 Jun 5. doi: 10.1007/s00415-024-12478. PubMed
HERAUD C, Bresch S, Landes-Chateau C, Bourg V, et al Rituximab alone is as effective as associated with steroids on naive patients
with generalized myasthenia gravis.
J Neurol. 2024 Jun 5. doi: 10.1007/s00415-024-12454. PubMedAbstract available
STARK AJ, Mobley BC, Eaton JE Progressive leukoencephalopathy as a manifestation of primary angiitis of the
central nervous system: case report and review of the literature.
J Neurol. 2024;271:3648-3652. PubMedAbstract available
May 2024
PORTACCIO E, Betti M, De Meo E, Addazio I, et al Progression independent of relapse activity in relapsing multiple sclerosis:
impact and relationship with secondary progression.
J Neurol. 2024 May 28. doi: 10.1007/s00415-024-12448. PubMedAbstract available
HUANG W, Zhang H, Li X, Zhang J, et al Prognostic factors underlying the development of drug-resistant epilepsy in
patients with autoimmune encephalitis: a retrospective cohort study.
J Neurol. 2024 May 27. doi: 10.1007/s00415-024-12432. PubMedAbstract available
CHAE J, Nguyen TT, Oh SY Quantification of saccadic fatigability and diagnostic efficacy for myasthenia
gravis.
J Neurol. 2024 May 26. doi: 10.1007/s00415-024-12461. PubMedAbstract available
MONTEIRO I, Nicolella V, Fiorenza M, Novarella F, et al The ocrelizumab wearing-off phenomenon is associated with reduced
immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434. PubMedAbstract available
FJORDSIDE L, Nissen MS, Florescu AM, Storgaard M, et al Validation of a risk score to differentiate autoimmune and viral encephalitis: a
Nationwide Cohort Study in Denmark.
J Neurol. 2024 May 18. doi: 10.1007/s00415-024-12392. PubMedAbstract available
CORTESE R, Battaglini M, Stromillo ML, Luchetti L, et al Regional hippocampal atrophy reflects memory impairment in patients with early
relapsing remitting multiple sclerosis.
J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12290. PubMedAbstract available
WOLF E, Wicklein R, Aly L, Schmaderer C, et al Optical coherence tomography angiography suggests different retinal pathologies
in multiple sclerosis and Sjogren's syndrome.
J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12414. PubMedAbstract available
FREEDMAN DE, Oh J, Kiss A, Puopolo J, et al The influence of depression and anxiety on cognition in people with multiple
sclerosis: a cross-sectional analysis.
J Neurol. 2024 May 11. doi: 10.1007/s00415-024-12409. PubMedAbstract available
BARDEL B, Creange A, Bonardet N, Bapst B, et al Motor function in multiple sclerosis assessed by navigated transcranial magnetic
stimulation mapping.
J Neurol. 2024 May 6. doi: 10.1007/s00415-024-12398. PubMedAbstract available
GALPERIN I, Buzaglo D, Gazit E, Shimoni N, et al Gait and heart rate: do they measure trait or state physical fatigue in people
with multiple sclerosis?
J Neurol. 2024 May 2. doi: 10.1007/s00415-024-12339. PubMedAbstract available
PREZIOSA P, Rocca MA, Filippi M Radiologically isolated syndromes: to treat or not to treat?
J Neurol. 2024;271:2370-2378. PubMedAbstract available
LEHNERER S, Herdick M, Stegherr R, Gerischer L, et al Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient's
perspective.
J Neurol. 2024;271:2824-2839. PubMedAbstract available
KONEN FF, Jendretzky KF, Ratuszny D, Schuppner R, et al Ravulizumab in myasthenic crisis: the first case report.
J Neurol. 2024;271:2898-2901. PubMed
BURTON JM, Youn S, Al-Ani A, Costello F, et al Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody
testing in cerebrospinal fluid.
J Neurol. 2024;271:2662-2671. PubMedAbstract available
HEIDER D, Stetefeld H, Meisel A, Bosel J, et al POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic
crisis.
J Neurol. 2024;271:2875-2879. PubMed
RISI M, Greco G, Masciocchi S, Rigoni E, et al MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a
clinical-laboratory assessment.
J Neurol. 2024;271:2840-2843. PubMedAbstract available
DOUBROVINSKAJA S, Korporal-Kuhnke M, Jarius S, Haas J, et al Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab
for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal
outcome.
J Neurol. 2024;271:2866-2870. PubMedAbstract available
ROCCA MA, Romano F, Tedone N, Filippi M, et al Advanced neuroimaging techniques to explore the effects of motor and cognitive
rehabilitation in multiple sclerosis.
J Neurol. 2024 May 1. doi: 10.1007/s00415-024-12395. PubMedAbstract available
April 2024
DIMAURO KA, Swetlik C, Cohen JA Management of multiple sclerosis in older adults: review of current evidence and
future perspectives.
J Neurol. 2024 Apr 30. doi: 10.1007/s00415-024-12384. PubMedAbstract available
ROSENSTEIN I, Nordin A, Sabir H, Malmestrom C, et al Association of serum glial fibrillary acidic protein with progression independent
of relapse activity in multiple sclerosis.
J Neurol. 2024 Apr 26. doi: 10.1007/s00415-024-12389. PubMedAbstract available
FONTE J, Stabile A, de Curtis M, Di Giacomo R, et al Seizures in autoimmune-associated epilepsy: a long-term video-EEG monitoring
study.
J Neurol. 2024 Apr 24. doi: 10.1007/s00415-024-12385. PubMed
NAUTA IM, van Dam M, Bertens D, Kessels RPC, et al Improved quality of life and psychological symptoms following mindfulness and
cognitive rehabilitation in multiple sclerosis and their mediating role for
cognition: a randomized controlled trial.
J Neurol. 2024 Apr 23. doi: 10.1007/s00415-024-12327. PubMedAbstract available
SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al Effect of siponimod on lymphocyte subsets in active secondary progressive
multiple sclerosis and clinical implications.
J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362. PubMedAbstract available
HIRT J, Dembowska K, Woelfle T, Axfors C, et al Clinical trial evidence of quality-of-life effects of disease-modifying therapies
for multiple sclerosis: a systematic analysis.
J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366. PubMedAbstract available
SINGER BA, Feng J, Chiong-Rivero H Early use of high-efficacy therapies in multiple sclerosis in the United States:
benefits, barriers, and strategies for encouraging adoption.
J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305. PubMedAbstract available
ZHANG Y, Liu D, Zhang Z, Huang X, et al Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance
of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia
gravis: a case report.
J Neurol. 2024 Apr 11. doi: 10.1007/s00415-024-12367. PubMed
STALTER J, Pars K, Witt K Accelerated long-term forgetting reveals everyday memory deficits in early-stage
multiple sclerosis.
J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359. PubMedAbstract available
MARTINEZ-MARTINEZ L, Lacruz AC, Querol L, Cortes-Vicente E, et al Inter-laboratory comparison of routine autoantibody detection methods for
autoimmune neuropathies and myasthenia gravis.
J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12317. PubMedAbstract available
CELIK M, Baba C, Irmak C, Ozakbas S, et al Risk of hepatitis B virus reactivation in people with multiple sclerosis treated
with ocrelizumab: an observational study from Turkey.
J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333. PubMedAbstract available
STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al Prevalence and epidemiology of stroke in patients with multiple sclerosis: a
systematic review and meta-analysis.
J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331. PubMedAbstract available
TERAYAMA A, Kuwahara M, Yoshikawa K, Yamagishi Y, et al Takotsubo cardiomyopathy in Guillain-Barre syndrome.
J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12295. PubMedAbstract available
MAIDA E, Moccia M, Palladino R, Borriello G, et al ChatGPT vs. neurologists: a cross-sectional study investigating preference,
satisfaction ratings and perceived empathy in responses among people living with
multiple sclerosis.
J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328. PubMedAbstract available
SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al Pregnancy effect on disease activity in women with multiple sclerosis treated
with cladribine.
J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291. PubMedAbstract available
GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al Can treatment adverse events be optimized by switching between different
sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342. PubMed
MCWILLIAM O, Gramkow MH, Blaabjerg M, Clemmensen FK, et al Differentiating anti-IgLON5 disease and Lewy body dementia: a systematic review.
J Neurol. 2024;271:1707-1716. PubMedAbstract available
WANG Y, Hu C, Aljarallah S, Reyes Mantilla M, et al Expanding clinical profiles and prognostic markers in stiff person syndrome
spectrum disorders.
J Neurol. 2024;271:1861-1872. PubMedAbstract available
TEDONE N, Vizzino C, Meani A, Gallo A, et al The brief repeatable battery of neuropsychological tests (BRB-N) version a:
update of Italian normative data from the Italian Neuroimaging Network Initiative
(INNI).
J Neurol. 2024;271:1813-1823. PubMedAbstract available
GLASER A, Butzkueven H, van der Walt A, Gray O, et al Big Multiple Sclerosis Data network: an international registry research network.
J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303. PubMedAbstract available
HUA T, Fan H, Duan Y, Tian D, et al Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder
and multiple sclerosis.
J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281. PubMedAbstract available
March 2024
GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316. PubMedAbstract available
SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to
serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299. PubMedAbstract available
MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al Early prediction of unfavorable evolution after a first clinical episode
suggestive of multiple sclerosis: the EUMUS score.
J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304. PubMedAbstract available
ZHANG H, Ma J, Feng Y, Ma H, et al Efgartigimod in the treatment of Guillain-Barre syndrome.
J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12321. PubMedAbstract available
FUCHS L, Shelly S, Vigiser I, Kolb H, et al Real-World experience with efgartigimod in patients with myasthenia gravis.
J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12293. PubMedAbstract available
PILOTTO S, Floris M, Solla P, Pugliatti M, et al Determinants of self-perceived quality of life in mildly disabled multiple
sclerosis patients: a cross-sectional study.
J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244. PubMedAbstract available
LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al Correction to: Neurofilament light in plasma is a potential biomarker of central
nervous system involvement in systemic lupus erythematosus.
J Neurol. 2024 Mar 23. doi: 10.1007/s00415-024-12238. PubMed
GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al Persons with multiple sclerosis older than 55 years: an analysis from the German
MS registry.
J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286. PubMedAbstract available
ALBERGONI M, Pagani E, Preziosa P, Meani A, et al Thalamic nuclei volume partially mediates the effects of aerobic capacity on
fatigue in people with multiple sclerosis.
J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277. PubMedAbstract available
ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al Correction to: The impact of metformin use on the outcomes of relapse?remitting
multiple sclerosis patients receiving interferon beta 1a: an exploratory
prospective phase II open?label randomized controlled trial.
J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249. PubMed
VILASECA A, Farina A, Villagran-Garcia M, Pegat A, et al Neurological autoimmunity in melanoma patients: a comparison between those
exposed and non-exposed to immune checkpoint inhibitors.
J Neurol. 2024 Mar 11. doi: 10.1007/s00415-024-12252. PubMedAbstract available
KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al The cognitive relevance of non-lesional damage to cortical networks in people
with multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240. PubMedAbstract available
HEGEN H, Berek K, Deisenhammer F, Berger T, et al Sex impacts treatment decisions in multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270. PubMedAbstract available
HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al Evaluation of a self-administered iPad((R))-based processing speed assessment for
people with multiple sclerosis in a clinical routine setting.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274. PubMedAbstract available
ZID Y, Robertson NP Extended interval dosing strategies in multiple sclerosis: insights from
natalizumab and ocrelizumab trials.
J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273. PubMed
LI J, Wu X, Chu T, Tan X, et al The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a
systematic review and meta-analysis.
J Neurol. 2024 Mar 3. doi: 10.1007/s00415-024-12247. PubMedAbstract available
GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al Early intensive versus escalation treatment in patients with relapsing-remitting
multiple sclerosis in Austria.
J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256. PubMedAbstract available
February 2024
SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al Risk of secondary progression in patients with highly active multiple sclerosis
treated with natalizumab: a real-life study.
J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266. PubMedAbstract available
TOLJAN K, Briggs FBS Male sexual and reproductive health in multiple sclerosis: a scoping review.
J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250. PubMedAbstract available
LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al A randomized controlled trial of oral antipyretic treatment to reduce overheating
during exercise in adults with multiple sclerosis.
J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147. PubMedAbstract available
VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al Identifying and understanding cognitive profiles in multiple sclerosis: a role
for visuospatial memory functioning.
J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227. PubMedAbstract available
NGUYEN TT, Chae J, Kang JJ, Oh SY, et al Saccadic fatigue as an early indicator for diagnosing myasthenia gravis.
J Neurol. 2024 Feb 25. doi: 10.1007/s00415-024-12262. PubMed
WEISS MD, Freimer M, Leite MI, Maniaol A, et al Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
J Neurol. 2024 Feb 24. doi: 10.1007/s00415-024-12209. PubMedAbstract available
OHNARI K, Hashimoto T, Iwanaka Y, Ohnari K, et al Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a
case report.
J Neurol. 2024 Feb 23. doi: 10.1007/s00415-024-12245. PubMed
GREGULETZ P, Plotz M, Baade-Buttner C, Bien CG, et al Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12224. PubMedAbstract available
CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated
multiple sclerosis patient.
J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226. PubMed
BIANCHI A, Matranga D, Patti F, Maniscalco L, et al The role of ethnicity and native-country income in multiple sclerosis: the
Italian multicentre study (MS-MigIT).
J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214. PubMedAbstract available
HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al Prodromal multiple sclerosis: considerations and future utility.
J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173. PubMedAbstract available
VANCURA J, Boyd NK, Vogel BN, Nagesh D, et al Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in
aicardi-goutieres syndrome.
J Neurol. 2024;271:1019-1022. PubMed
January 2024
BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al Ocrelizumab reduces cortical and deep grey matter loss compared to the
S1P-receptor modulator in multiple sclerosis.
J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179. PubMedAbstract available
BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI
patterns and its development over time.
J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185. PubMedAbstract available
NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al Neurophysiological brain function predicts response to cognitive rehabilitation
and mindfulness in multiple sclerosis: a randomized trial.
J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183. PubMedAbstract available
CENSI S, Bisaccia G, Gallina S, Tomassini V, et al Guillain-Barre syndrome and COVID-19 vaccination: a systematic review and
meta-analysis.
J Neurol. 2024 Jan 17. doi: 10.1007/s00415-024-12186. PubMedAbstract available
FENG G, Posa S, Sureshkumar A, Simpson S, et al Experiences of people with multiple sclerosis and clinicians in using cognitive
behavioural therapies for hidden symptoms: a systematic review and
meta-aggregation.
J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116. PubMedAbstract available
ZHENG P, Sandroff BM, Motl RW Free-living ambulatory physical activity and cognitive function in multiple
sclerosis: the significance of step rate vs. step volume.
J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169. PubMedAbstract available
MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al Humoral response after accelerated schedule of HBV vaccination in MS patients
before anti-CD20 therapy.
J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175. PubMed
TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al Nutritional interventional studies in patients with multiple sclerosis: a scoping
review of the current clinical evidence.
J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140. PubMedAbstract available
LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al Late-onset multiple sclerosis: disability trajectories in relapsing-remitting
patients of the Italian MS Registry.
J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152. PubMedAbstract available
FAVRUZZO F, Palmieri A, Giopato F, Cardellini D, et al Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and
Varicella-Zoster virus infections: a case report.
J Neurol. 2024;271:75-78. PubMed
NEUMANN B, Angstwurm K, Dohmen C, Mergenthaler P, et al Weaning and extubation failure in myasthenic crisis: a multicenter analysis.
J Neurol. 2024;271:564-574. PubMedAbstract available
WIESENFARTH M, Stamminger T, Zizer E, Tumani H, et al Neurological manifestation of HEV infection: still a rare disease entity?
J Neurol. 2024;271:386-394. PubMedAbstract available
MOSER T, Zimmermann G, Baumgartner A, Berger T, et al Long-term outcome of natalizumab-associated progressive multifocal
leukoencephalopathy in Austria: a nationwide retrospective study.
J Neurol. 2024;271:374-385. PubMedAbstract available
KUMPFEL T, Giglhuber K, Aktas O, Ayzenberg I, et al Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders
(NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group
(NEMOS). Part II: Attack therapy and long-term management.
J Neurol. 2024;271:141-176. PubMedAbstract available
December 2023
AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al Tumefactive demyelinating lesions: a challenging first manifestation of multiple
sclerosis.
J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164. PubMed
LIU M, Ren H, Wang L, Fan S, et al Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a
prospective cohort study.
J Neurol. 2023 Dec 23. doi: 10.1007/s00415-023-12128. PubMedAbstract available
IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a
study from the Italian MS Registry.
J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137. PubMedAbstract available
ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al Predicting disease severity in multiple sclerosis using multimodal data and
machine learning.
J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132. PubMedAbstract available
MISTRI D, Valsasina P, Storelli L, Filippi M, et al Monoaminergic network dysfunction and development of depression in multiple
sclerosis: a longitudinal investigation.
J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138. PubMedAbstract available
HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based
study.
J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047. PubMedAbstract available
COVEY TJ, Golan D, Sergott R, Wilken J, et al Peering further into the mind's eye: combining visual evoked potential and
optical coherence tomography measures enhances insight into the variance in
cognitive functioning in multiple sclerosis.
J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075. PubMedAbstract available
ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al Baseline serum neurofilament light chain levels differentiate aggressive from
benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up
cohort.
J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135. PubMedAbstract available
TSAI CC, Jette S, Tremlett H Disease-modifying therapies used to treat multiple sclerosis and the gut
microbiome: a systematic review.
J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107. PubMedAbstract available
ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al The impact of metformin use on the outcomes of relapse-remitting multiple
sclerosis patients receiving interferon beta 1a: an exploratory prospective phase
II open-label randomized controlled trial.
J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113. PubMedAbstract available
November 2023
MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al Body mass, neuro-hormonal stress processing, and disease activity in lean to
obese people with multiple sclerosis.
J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100. PubMedAbstract available
MISTRI D, Tedone N, Biondi D, Vizzino C, et al Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102. PubMedAbstract available
JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al Disease-modifying treatment, long-term outcomes and transition to progressive
multiple sclerosis: data based on the New York State MS Consortium.
J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099. PubMedAbstract available
BISECCO A, Matrone F, Capobianco M, De Luca G, et al COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing
of ocrelizumab in MS patients.
J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084. PubMedAbstract available
SUN Y, Li G, Liu X, Zhao X, et al Cerebral glucose hypometabolism and hypoperfusion of cingulate gyrus: an imaging
biomarker of autoimmune encephalitis with psychiatric symptoms.
J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12051. PubMedAbstract available
KENNEDY PGE, George W, Yu X The elusive nature of the oligoclonal bands in multiple sclerosis.
J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081. PubMedAbstract available
DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on
relapse risk after the third booster dose.
J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034. PubMedAbstract available
FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
J Neurol. 2023;270:5392-5397. PubMedAbstract available
JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case
of a patient with multiple sclerosis under fingolimod.
J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055. PubMed
October 2023
MANTERO V, Cordano C, Balgera R, Basilico P, et al Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082. PubMed
KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis
of the phase 2 randomized clinical trial and its extension.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943. PubMedAbstract available
DELGADO SR, Faissner S, Linker RA, Rammohan K, et al Key characteristics of anti-CD20 monoclonal antibodies and clinical implications
for multiple sclerosis treatment.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007. PubMedAbstract available
RIVEL M, Achiron A, Stern Y, Zeilig G, et al Emotional burden among MS patients: associations between specific chronic pain
diagnoses and psychological features.
J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048. PubMedAbstract available
ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al Identification and management of subclinical disease activity in early multiple
sclerosis: a review.
J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021. PubMedAbstract available
ZINGANELL A, Gobel G, Berek K, Hofer B, et al Multiple sclerosis in the elderly: a retrospective cohort study.
J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041. PubMedAbstract available
SELMAJ K, Cree BAC, Barnett M, Thompson A, et al Multiple sclerosis: time for early treatment with high-efficacy drugs.
J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969. PubMedAbstract available
RAVANO V, Piredda GF, Krasensky J, Andelova M, et al Tract-wise microstructural analysis informs on current and future disability in
early multiple sclerosis.
J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023. PubMedAbstract available
MANZANO GS, McEntire C, Venna N Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis.
J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-11992. PubMed
ZHANG Z, Wang Z, Du X, Huang X, et al Refractory generalized myasthenia gravis treated successfully with telitacicept:
two cases report.
J Neurol. 2023 Oct 7. doi: 10.1007/s00415-023-12036. PubMed
KRAKER JA, Chen JJ An update on optic neuritis.
J Neurol. 2023;270:5113-5126. PubMedAbstract available
BRISCA G, Marini C, Buratti S, Mariani M, et al Acute pediatric encephalitis: etiology, course, and outcome of a 12-year
single-center immunocompetent cohort.
J Neurol. 2023;270:5034-5047. PubMedAbstract available
WANG R, Sun D, Du Q, Shi Z, et al Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum
disorder with cluster attack: a case report.
J Neurol. 2023;270:5085-5089. PubMed
September 2023
RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995. PubMedAbstract available
LI Y, Saul A, Taylor B, Ponsonby AL, et al Examining the environmental risk factors of progressive-onset and relapsing-onset
multiple sclerosis: recruitment challenges, potential bias, and statistical
strategies.
J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980. PubMedAbstract available
KERNER C, Kotobelli K, Appleby BS, Cohen ML, et al Pathological findings in autoimmune encephalitis autopsy specimens from cases of
suspected prion disease.
J Neurol. 2023 Sep 27. doi: 10.1007/s00415-023-12003. PubMedAbstract available
WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al Multimodal MRI study on the relation between WM integrity and connected GM
atrophy and its effect on disability in early multiple sclerosis.
J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937. PubMedAbstract available
FILIPPI M, Grimaldi L, Conte A, Totaro R, et al Intravenous or subcutaneous natalizumab in patients with relapsing-remitting
multiple sclerosis: investigation on efficiency and savings-the EASIER study.
J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955. PubMedAbstract available
GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al Characterizing cognitive function in patients with autoimmune encephalitis: an
Australian prospective study.
J Neurol. 2023 Sep 14. doi: 10.1007/s00415-023-11967. PubMedAbstract available
MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al Robust real-world evidence: optimising disease-modifying treatments for multiple
sclerosis.
J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984. PubMed
DI STEFANO V, Alonge P, Rini N, Militello M, et al Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in
stiff-person syndrome.
J Neurol. 2023 Sep 8. doi: 10.1007/s00415-023-11970. PubMedAbstract available
JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al Modifiable risk factors for multiple sclerosis have consistent directions of
effect across diverse ethnic backgrounds: a nested case-control study in an
English population-based cohort.
J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971. PubMedAbstract available